Nextcure Stock Performance
| NXTC Stock | USD 11.92 0.73 5.77% |
On a scale of 0 to 100, NextCure holds a performance score of 7. The company secures a Beta (Market Risk) of 1.25, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NextCure will likely underperform. Please check NextCure's semi variance, as well as the relationship between the daily balance of power and price action indicator , to make a quick decision on whether NextCure's current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NextCure are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, NextCure exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.77) | Five Day Return (5.25) | Year To Date Return (10.24) | Ten Year Return (95.01) | All Time Return (95.01) |
Last Split Factor 1:12 | Last Split Date 2025-07-14 |
1 | Why analysts remain bullish on NextCure Inc. stock - July 2025 PostEarnings Technical Confirmation Alerts - newser.com | 10/31/2025 |
2 | How NextCure Inc. stock reacts to inflationary pressures - Take Profit Low Risk Entry Point Tips - newser.com | 11/04/2025 |
3 | Ladenburg Thalmann Upgrades NextCure - Nasdaq | 11/07/2025 |
4 | NextCure Announces 21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules | 11/12/2025 |
5 | NextCure Announces Closing of 21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts | 11/17/2025 |
6 | Piper Sandler Keeps Their Buy Rating on NextCure - The Globe and Mail | 11/25/2025 |
7 | NextCure Trading Up 4.9 percent Still a Buy | 12/11/2025 |
8 | Will NextCure Inc. stock remain a Wall Street favorite - July 2025 Update Consistent Profit Trading Strategies - DonanmHaber | 12/19/2025 |
9 | NextCure Provides Business Update | 01/23/2026 |
| Begin Period Cash Flow | 13.1 M | |
| Total Cashflows From Investing Activities | 55.3 M |
NextCure Relative Risk vs. Return Landscape
If you would invest 927.00 in NextCure on October 27, 2025 and sell it today you would earn a total of 265.00 from holding NextCure or generate 28.59% return on investment over 90 days. NextCure is currently generating 0.6415% in daily expected returns and assumes 7.133% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than NextCure, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NextCure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NextCure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NextCure, and traders can use it to determine the average amount a NextCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average NextCure is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NextCure by adding it to a well-diversified portfolio.
NextCure Fundamentals Growth
NextCure Stock prices reflect investors' perceptions of the future prospects and financial health of NextCure, and NextCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NextCure Stock performance.
| Return On Equity | -1.17 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | 17.09 M | ||||
| Shares Outstanding | 3.51 M | ||||
| Price To Earning | (25.44) X | ||||
| Price To Book | 1.77 X | ||||
| Price To Sales | 9.52 X | ||||
| Gross Profit | (54.2 M) | ||||
| EBITDA | (54.34 M) | ||||
| Net Income | (55.65 M) | ||||
| Cash And Equivalents | 185.49 M | ||||
| Cash Per Share | 6.68 X | ||||
| Total Debt | 5.95 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 33.87 X | ||||
| Book Value Per Share | 8.84 X | ||||
| Cash Flow From Operations | (40.8 M) | ||||
| Earnings Per Share | (23.81) X | ||||
| Market Capitalization | 41.79 M | ||||
| Total Asset | 80.86 M | ||||
| Retained Earnings | (380.14 M) | ||||
| Working Capital | 62.23 M | ||||
| Current Asset | 46.99 M | ||||
| Current Liabilities | 5.53 M | ||||
About NextCure Performance
By analyzing NextCure's fundamental ratios, stakeholders can gain valuable insights into NextCure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NextCure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NextCure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (0.96) | (1.01) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (0.98) | (0.93) |
Things to note about NextCure performance evaluation
Checking the ongoing alerts about NextCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NextCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NextCure is way too risky over 90 days horizon | |
| NextCure appears to be risky and price may revert if volatility continues | |
| NextCure has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (55.65 M) with loss before overhead, payroll, taxes, and interest of (54.2 M). | |
| NextCure currently holds about 185.49 M in cash with (40.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68. | |
| NextCure has a frail financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway |
- Analyzing NextCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NextCure's stock is overvalued or undervalued compared to its peers.
- Examining NextCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NextCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NextCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NextCure's stock. These opinions can provide insight into NextCure's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |